Biocare Medical and Bethyl Laboratories Announces the Launch of TIGIT IVD Rabbit Monoclonal Antibody for Immunohistochemical Applications

August, 4 2020 – Biocare Medical LLC, a leading provider of innovative, automated immunohistochemistry (IHC) reagents and instrumentation, in collaboration with Bethyl Laboratories announces the release of a new rabbit monoclonal antibody, TIGIT [BLR047F] antibody for in vitro diagnostic (IVD) use in the qualitative identification of the TIGIT protein by immunohistochemistry (IHC) in formalin-fixed paraffin-embedded (FFPE) human tissues.

TIGIT plays an important role in transplantation tolerance and tumor immune surveillance. Several studies indicate that TIGIT exhibits a synergistic function with the PD-1/PD-L1 pathway in the inhibition of T cell proliferation. The use of TIGIT, in conjunction with other checkpoint receptors, such as PD-1, has shown to be a promising marker for immunotherapy.

"We are excited for the release of an IVD grade TIGIT [BL074F] antibody for clinical application; the Bethyl clone [BLR047F] has been shown to display high sensitivity and specificity based on our internal research," said Dr. Jason Ramos, Vice President – Reagent Research and Development at Biocare Medical.

We believe that our new TIGIT IVD antibody will be a cost-effective IHC solution to the pharmaceutical and biotech research institutions requiring an IVD grade quality in early-stage research and companion diagnostics development.

TIGIT [BLR047F] is an IVD antibody available in a concentrate format to support titration by end-users as well as a ready-to-use predilute format. TIGIT [BLR047F] antibody is commercially available for immediate sale within the domestic US and European Union.

Read the Entire Press Release on Biocare Medical

Stay in the know!

Sign up to receive the latest news and information from Fortis Life Sciences.

Sign Up